Does the media refer more to HRMY or SPRY?

In the previous week, ARS Pharmaceuticals had 12 more articles in the media than Harmony Biosciences. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 7 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.54 beat ARS Pharmaceuticals' score of 0.09 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor OCUL or SPRY?

In the previous week, ARS Pharmaceuticals had 13 more articles in the media than Ocular Therapeutix. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 6 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.57 beat ARS Pharmaceuticals' score of 0.09 indicating that Ocular Therapeutix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ocular Therapeutix 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, SPRY or HCM?

HUTCHMED has higher revenue and earnings than ARS Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ARS Pharmaceuticals $116.93M 4.81 -$171.30M -$2.18 N/A HUTCHMED $548.51M 3.90 $456.91M N/A N/A

Does the media favor SPRY or HCM?

In the previous week, ARS Pharmaceuticals had 17 more articles in the media than HUTCHMED. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.01 beat ARS Pharmaceuticals' score of 0.09 indicating that HUTCHMED is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor GHRS or SPRY?

In the previous week, ARS Pharmaceuticals had 18 more articles in the media than GH Research. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 1 mentions for GH Research. ARS Pharmaceuticals' average media sentiment score of 0.09 beat GH Research's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SPRY or CMPS?

In the previous week, ARS Pharmaceuticals had 15 more articles in the media than Compass Pathways. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 1.16 beat ARS Pharmaceuticals' score of 0.09 indicating that Compass Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Pathways 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ARS Pharmaceuticals (SPRY) Competitors

$5.66 +0.31 (+5.87%)

As of 03:31 PM Eastern

Compare

SPRY vs. HRMY, OCUL, HCM, GHRS, and CMPS

Should you buy ARS Pharmaceuticals stock or one of its competitors? ARS Pharmaceuticals's main competitors and comparable companies include Harmony Biosciences (HRMY), Ocular Therapeutix (OCUL), HUTCHMED (HCM), GH Research (GHRS), and Compass Pathways (CMPS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does ARS Pharmaceuticals compare to Harmony Biosciences?

Harmony Biosciences (NASDAQ:HRMY) and ARS Pharmaceuticals (NASDAQ:SPRY) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Harmony Biosciences has a net margin of 18.88% compared to ARS Pharmaceuticals' net margin of -184.24%. Harmony Biosciences' return on equity of 20.06% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

In the previous week, ARS Pharmaceuticals had 12 more articles in the media than Harmony Biosciences. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 7 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.54 beat ARS Pharmaceuticals' score of 0.09 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	6 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Harmony Biosciences has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45M	2.59	$158.69M	$3.08	12.54
ARS Pharmaceuticals	$116.93M	4.81	-$171.30M	-$2.18	N/A

Harmony Biosciences currently has a consensus price target of $45.50, suggesting a potential upside of 17.77%. ARS Pharmaceuticals has a consensus price target of $28.20, suggesting a potential upside of 398.32%. Given ARS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Harmony Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Harmony Biosciences beats ARS Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Ocular Therapeutix?

Ocular Therapeutix (NASDAQ:OCUL) and ARS Pharmaceuticals (NASDAQ:SPRY) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Ocular Therapeutix currently has a consensus target price of $25.75, suggesting a potential upside of 134.20%. ARS Pharmaceuticals has a consensus target price of $28.20, suggesting a potential upside of 398.32%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Ocular Therapeutix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

ARS Pharmaceuticals has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$51.95M	46.48	-$265.94M	-$1.42	N/A
ARS Pharmaceuticals	$116.93M	4.81	-$171.30M	-$2.18	N/A

ARS Pharmaceuticals has a net margin of -184.24% compared to Ocular Therapeutix's net margin of -579.10%. Ocular Therapeutix's return on equity of -59.89% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-579.10%	-59.89%	-45.99%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Ocular Therapeutix has a beta of 0.93, indicating that its stock price is 7% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 13 more articles in the media than Ocular Therapeutix. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 6 mentions for Ocular Therapeutix. Ocular Therapeutix's average media sentiment score of 0.57 beat ARS Pharmaceuticals' score of 0.09 indicating that Ocular Therapeutix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by company insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

ARS Pharmaceuticals beats Ocular Therapeutix on 9 of the 16 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to HUTCHMED?

ARS Pharmaceuticals (NASDAQ:SPRY) and HUTCHMED (NASDAQ:HCM) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

ARS Pharmaceuticals has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market.

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 3.6% of HUTCHMED shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

HUTCHMED has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. HUTCHMED's return on equity of 0.00% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%
HUTCHMED	N/A	N/A	N/A

HUTCHMED has higher revenue and earnings than ARS Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$116.93M	4.81	-$171.30M	-$2.18	N/A
HUTCHMED	$548.51M	3.90	$456.91M	N/A	N/A

ARS Pharmaceuticals currently has a consensus price target of $28.20, suggesting a potential upside of 398.32%. HUTCHMED has a consensus price target of $14.87, suggesting a potential upside of 21.31%. Given ARS Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe ARS Pharmaceuticals is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
HUTCHMED	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.17

In the previous week, ARS Pharmaceuticals had 17 more articles in the media than HUTCHMED. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 1.01 beat ARS Pharmaceuticals' score of 0.09 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ARS Pharmaceuticals beats HUTCHMED on 8 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to GH Research?

GH Research (NASDAQ:GHRS) and ARS Pharmaceuticals (NASDAQ:SPRY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

GH Research has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market.

GH Research presently has a consensus target price of $45.00, indicating a potential upside of 56.06%. ARS Pharmaceuticals has a consensus target price of $28.20, indicating a potential upside of 398.32%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ARS Pharmaceuticals had 18 more articles in the media than GH Research. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 1 mentions for GH Research. ARS Pharmaceuticals' average media sentiment score of 0.09 beat GH Research's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

GH Research has higher earnings, but lower revenue than ARS Pharmaceuticals. GH Research is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$1.00	N/A
ARS Pharmaceuticals	$116.93M	4.81	-$171.30M	-$2.18	N/A

56.9% of GH Research shares are owned by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GH Research has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. GH Research's return on equity of -20.07% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-20.07%	-19.41%
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%

Summary

GH Research beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Compass Pathways?

ARS Pharmaceuticals (NASDAQ:SPRY) and Compass Pathways (NASDAQ:CMPS) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

ARS Pharmaceuticals has higher revenue and earnings than Compass Pathways. Compass Pathways is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$116.93M	4.81	-$171.30M	-$2.18	N/A
Compass Pathways	N/A	N/A	-$287.86M	-$4.62	N/A

ARS Pharmaceuticals has a beta of 0.98, indicating that its share price is 2% less volatile than the broader market. Comparatively, Compass Pathways has a beta of 2.5, indicating that its share price is 150% more volatile than the broader market.

In the previous week, ARS Pharmaceuticals had 15 more articles in the media than Compass Pathways. MarketBeat recorded 19 mentions for ARS Pharmaceuticals and 4 mentions for Compass Pathways. Compass Pathways' average media sentiment score of 1.16 beat ARS Pharmaceuticals' score of 0.09 indicating that Compass Pathways is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	16 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Pathways	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ARS Pharmaceuticals currently has a consensus price target of $28.20, indicating a potential upside of 398.32%. Compass Pathways has a consensus price target of $23.36, indicating a potential upside of 57.51%. Given ARS Pharmaceuticals' higher probable upside, research analysts clearly believe ARS Pharmaceuticals is more favorable than Compass Pathways.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Compass Pathways	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.88

Compass Pathways has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -184.24%. Compass Pathways' return on equity of -49.63% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-184.24%	-256.67%	-69.63%
Compass Pathways	N/A	-49.63%	-13.08%

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.2% of Compass Pathways shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 2.8% of Compass Pathways shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

ARS Pharmaceuticals and Compass Pathways tied by winning 8 of the 16 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRY vs. The Competition

Export

Metric	ARS Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$561.38M	$12.55B	$7.32B	$12.76B
Dividend Yield	N/A	2.61%	2.54%	10.78%
P/E Ratio	-2.59	778.11	271.20	24.17
Price / Sales	4.81	960.06	696.57	128.56
Price / Cash	N/A	15.47	29.03	36.89
Price / Book	4.88	10.54	11.33	6.51
Net Income	-$171.30M	$2.80B	$3.46B	$347.63M
7 Day Performance	-10.10%	3.76%	3.12%	1.53%
1 Month Performance	-4.65%	6.32%	8.67%	5.17%
1 Year Performance	-58.08%	8.60%	27.37%	17.69%

ARS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRY ARS Pharmaceuticals	3.4839 of 5 stars	$5.66 +5.8%	$28.20 +398.3%	-60.4%	$561.38M	$116.93M	N/A	90	Trending News
HRMY Harmony Biosciences	4.4872 of 5 stars	$38.14 +0.1%	$45.50 +19.3%	+1.7%	$2.22B	$868.45M	12.38	200	Positive News
OCUL Ocular Therapeutix	3.0967 of 5 stars	$10.65 +6.1%	$25.75 +141.8%	-12.4%	$2.20B	$51.95M	N/A	230	High Trading Volume
HCM HUTCHMED	2.5184 of 5 stars	$12.56 +3.0%	$14.87 +18.4%	-24.3%	$2.13B	$548.51M	N/A	1,796	Positive News High Trading Volume
GHRS GH Research	1.9402 of 5 stars	$29.98 +1.7%	$45.00 +50.1%	+114.8%	$2.02B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRY) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. HRMY, OCUL, HCM, GHRS, and CMPS

How does ARS Pharmaceuticals compare to Harmony Biosciences?

Summary

How does ARS Pharmaceuticals compare to Ocular Therapeutix?

Summary

How does ARS Pharmaceuticals compare to HUTCHMED?

Summary

How does ARS Pharmaceuticals compare to GH Research?

Summary

How does ARS Pharmaceuticals compare to Compass Pathways?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. HRMY, OCUL, HCM, GHRS, and CMPS

How does ARS Pharmaceuticals compare to Harmony Biosciences?

Is HRMY or SPRY more profitable?

Does the media refer more to HRMY or SPRY?

Which has higher earnings and valuation, HRMY or SPRY?

Do analysts recommend HRMY or SPRY?

Which has more risk and volatility, HRMY or SPRY?

Do insiders and institutionals hold more shares of HRMY or SPRY?

Summary

How does ARS Pharmaceuticals compare to Ocular Therapeutix?

Do analysts recommend OCUL or SPRY?

Which has preferable earnings & valuation, OCUL or SPRY?

Is OCUL or SPRY more profitable?

Which has more risk & volatility, OCUL or SPRY?

Does the media favor OCUL or SPRY?

Do institutionals and insiders hold more shares of OCUL or SPRY?

Summary

How does ARS Pharmaceuticals compare to HUTCHMED?

Which has more risk & volatility, SPRY or HCM?

Do insiders and institutionals have more ownership in SPRY or HCM?

Is SPRY or HCM more profitable?

Which has preferable valuation & earnings, SPRY or HCM?

Do analysts rate SPRY or HCM?

Does the media favor SPRY or HCM?

Summary

How does ARS Pharmaceuticals compare to GH Research?

Which has more volatility & risk, GHRS or SPRY?

Do analysts prefer GHRS or SPRY?

Does the media favor GHRS or SPRY?

Which has stronger valuation & earnings, GHRS or SPRY?

Do institutionals and insiders have more ownership in GHRS or SPRY?

Is GHRS or SPRY more profitable?

Summary

How does ARS Pharmaceuticals compare to Compass Pathways?

Which has stronger earnings & valuation, SPRY or CMPS?

Which has more volatility and risk, SPRY or CMPS?

Does the media prefer SPRY or CMPS?

Do analysts recommend SPRY or CMPS?

Is SPRY or CMPS more profitable?

Do institutionals & insiders believe in SPRY or CMPS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools